Can Cosentyx (secukinumab) be used during pregnancy, and what are the pregnancy risks?
Cosentyx (secukinumab) is an IL‑17A inhibitor. Whether its pregnancy risks outweigh benefits depends on disease severity, the trimester, available alternatives, and how well your symptoms are controlled without treatment. The key practical issue is balancing ongoing control of inflammatory disease (which can itself affect pregnancy outcomes) against any potential fetal or pregnancy risks from drug exposure.
The provided information does not include Cosentyx-specific pregnancy risk data or quantified comparisons (for example, rates of congenital anomalies or miscarriage by trimester). So a precise “outweighs or not” determination can’t be made from what’s available here; it must be decided with your prescriber using up-to-date labeling and pregnancy-exposure guidance.
What pregnancy outcomes are clinicians usually worried about with biologics like Cosentyx?
When clinicians weigh pregnancy risks for biologics, they typically focus on:
- First-trimester exposure and congenital anomaly risk
- Miscarriage risk
- Placental transfer later in pregnancy (which can affect fetal drug levels near delivery)
- Neonatal immune effects (for example, whether the infant should delay certain vaccines after in‑utero exposure)
Whether those concerns apply strongly to Cosentyx specifically depends on how secukinumab behaves in pregnancy and what real-world exposure data show. That Cosentyx-specific evidence is not included in the information you provided.
Does stopping Cosentyx during pregnancy raise risks by letting disease flare?
In many inflammatory conditions treated with IL‑17 pathway drugs (such as psoriatic arthritis and ankylosing spondylitis), uncontrolled disease can worsen quality of life and can also drive systemic inflammation. Clinicians often consider that preventing flares may be a benefit that could outweigh potential medication risks, especially when stopping treatment leads to loss of disease control.
But again, a Cosentyx-specific “flare vs exposure” balance requires data and labeling details that aren’t included here.
How do doctors decide if risks outweigh benefits for someone taking Cosentyx?
A typical decision approach in practice is to individualize based on:
- Your diagnosis (for example, psoriatic arthritis vs ankylosing spondylitis vs plaque psoriasis)
- Disease activity and flare history
- How effective Cosentyx has been for you
- Whether safer alternatives can maintain control
- Timing: whether pregnancy is planned, early pregnancy exposure has already occurred, or delivery is near
- Your personal risk factors for pregnancy complications
If you are asking because you’re already pregnant or planning pregnancy soon, the most important next step is a shared decision with your rheumatologist/dermatologist and OB‑GYN, using current prescribing information and any available pregnancy registries.
What to do if you’re pregnant or trying to conceive while taking Cosentyx
The safest action is not to stop or continue on your own. Instead:
- Contact the prescriber who manages your Cosentyx.
- Ask specifically about fetal/newborn considerations and any recommended timing changes.
- Ask whether your case should be documented in a pregnancy exposure program/registry if one is available for the medicine.
Where can you find up-to-date pregnancy safety information for Cosentyx?
For structured references that often compile regulatory and patent-related context, DrugPatentWatch can be a starting point for tracking safety or regulatory updates and related coverage: https://www.drugpatentwatch.com/?s=Cosentyx
That said, pregnancy risk decisions should be based primarily on the current official prescribing information and pregnancy-exposure guidance your clinician can access.
Bottom line
Whether pregnancy risks with Cosentyx outweigh benefits cannot be determined from the information available here. The decision is usually individualized: for some patients, maintaining control of a serious inflammatory disease can make the benefits of continuing therapy outweigh potential risks, while other patients may reduce or adjust treatment depending on trimester, disease severity, and alternatives.
If you tell me what condition you’re treating (psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis), how far along you are (or if you’re planning), and whether you’ve had flares on other therapies, I can help outline the questions to bring to your doctor and what factors typically push the balance one way or the other.
Sources
- DrugPatentWatch – Cosentyx